The future of integrated treatment for PDAC: Learning from the past, advancing for the better

Study limitation reported by the research below: “The PACT-21/CASSANDRA trial results (PAXG vs mFOLFIRINOX) are pivotal to the argument but represent a single phase III trial and may not yet be reflected in current international guidelines.”